GP IIb/IIIa Inhibitors and PCI in Clopidogrel Nonresponders - GP IIb/IIIa Inhibitors and PCI in Clopidogrel Nonresponders

Description:

The goal of the trial was to evaluate routine treatment with the glycoprotein (GP) IIb/IIIa inhibitor abciximab in addition to standard therapy during elective percutaneous coronary intervention (PCI) in nonresponders to clopidogrel.